Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 170Carboplatin 131Cisplatin 80Paclitaxel 77Gemcitabine 74Pemetrexed 73Bevacizumab 62Docetaxel 56Fluorouracil 50Oxaliplatin 48Dexamethasone 44durvalumab 40Leucovorin 39Capecitabine 38atezolizumab 37130-nm albumin-bound paclitaxel 35Rituximab 34Cetuximab 34Nivolumab 33Fulvestrant 33Cyclophosphamide 32Injections 31Prednisone 29Lenalidomide 29enzalutamide 28venetoclax 25Letrozole 25Irinotecan 25pomalidomide 23daratumumab 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × 30 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡